Novo Nordisk A/S (CPH:NOVO.B)
Denmark
· Delayed Price · Currency is DKK 309.60
+3.80 (1.24%)
At close: Dec 5, 2025
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Rybelsus Revenue | 23.71B | 23.30B |
Log In |
Log In |
Log In | Upgrade
|
| Ozempic Revenue | 129.12B | 120.34B |
Log In |
Log In |
Log In | Upgrade
|
| Victoza Revenue | 4.02B | 5.48B |
Log In |
Log In |
Log In | Upgrade
|
| Total GLP-1 Revenue | 156.85B | 149.13B |
Log In |
Log In |
Log In | Upgrade
|
| Long-Acting Insulin Revenue | 19.21B | 19.10B |
Log In |
Log In |
Log In | Upgrade
|
| Premix Insulin Revenue | 10.67B | 10.79B |
Log In |
Log In |
Log In | Upgrade
|
| Fast-Acting Insulin Revenue | 19.72B | 18.52B |
Log In |
Log In |
Log In | Upgrade
|
| Human Insulin Revenue | 6.02B | 6.97B |
Log In |
Log In |
Log In | Upgrade
|
| Total Insulin Revenue | 55.62B | 55.37B |
Log In |
Log In |
Log In | Upgrade
|
| Other Diabetes Care Revenue | 1.86B | 2.12B |
Log In |
Log In |
Log In | Upgrade
|
| Total Diabetes Care Revenue | 214.33B | 206.62B |
Log In |
Log In |
Log In | Upgrade
|
| Wegovy Revenue | 77.11B | 58.21B |
Log In |
Log In |
Log In | Upgrade
|
| Saxenda Revenue | 4.20B | 6.94B |
Log In |
Log In |
Log In | Upgrade
|
| Total Obesity Care Revenue | 81.31B | 65.15B |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes & Obesity Care Revenue | 295.64B | 271.76B |
Log In |
Log In |
Log In | Upgrade
|
| Rare Blood Disorders Revenue | 12.33B | 12.14B |
Log In |
Log In |
Log In | Upgrade
|
| Rare Endocrine Disorders Revenue | 6.05B | 4.99B |
Log In |
Log In |
Log In | Upgrade
|
| Other Rare Disease Revenue | 1.58B | 1.51B |
Log In |
Log In |
Log In | Upgrade
|
| Rare Disease Revenue | 19.96B | 18.64B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | -509.97B | -478.38B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 315.60B | 290.40B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| US Revenue | 180.79B | 167.40B |
Log In |
Log In |
Log In | Upgrade
|
| EUCAN Revenue | 64.40B | 57.55B |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Revenue | 30.16B | 29.52B |
Log In |
Log In |
Log In | Upgrade
|
| APAC Revenue | 21.05B | 17.44B |
Log In |
Log In |
Log In | Upgrade
|
| China Revenue | 19.20B | 18.50B |
Log In |
Log In |
Log In | Upgrade
|
| Total International Revenue | 134.81B | 123.00B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | -134.81B | -123.00B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 315.60B | 290.40B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography 2
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| US Revenue (Pre-FY2024 Reporting) | 156.42B | 167.40B |
Log In |
Log In |
Log In | Upgrade
|
| Other North American Operations (NAO) Revenue | - | 10.77B |
Log In |
Log In |
Log In | Upgrade
|
| Total North American Operations (NAO) Revenue | - | 178.17B |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Revenue | - | 60.40B |
Log In |
Log In |
Log In | Upgrade
|
| China Revenue (Pre-FY2024 Reporting) | 19.20B | 18.50B |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Revenue | - | 33.33B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 315.60B | 290.40B |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Diabetes & Obesity Care Operating Profit | 131.44B | 127.72B |
Log In |
Log In |
Log In | Upgrade
|
| Rare Disease Operating Profit | 1.22B | 620.00M |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | 132.66B | 128.34B |
Log In |
Log In |
Log In | Upgrade
|